Related Experiment Video

Updated: Jun 14, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
13:51

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay

Published on: November 11, 2018

Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis

Kenneth L Scott1, Lynda Chin

  • 1Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|April 1, 2010
PubMed

Insights

Golgi phosphoprotein 3 (GOLPH3) is an oncoprotein that drives tumor growth by enhancing mTOR signaling. Understanding its role in vesicular trafficking and glycosylation may reveal new cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Golgi phosphoprotein 3 (GOLPH3) is an oncoprotein involved in vesicular trafficking.
  • The GOLPH3 gene is located on human chromosome 5p13 and frequently amplified in solid tumors.
  • GOLPH3 is a phosphorylated protein localized to the Golgi apparatus.

Purpose of the Study:

  • To investigate the role of GOLPH3 as an oncoprotein in cancer.
  • To explore the mechanisms by which GOLPH3 promotes tumor growth.
  • To identify potential therapeutic targets related to GOLPH3 function.

Main Methods:

  • Functional assays
  • Cell biological analyses
  • Biochemical analyses

Main Results:

  • GOLPH3 enhances the activity of the mammalian target of rapamycin (mTOR) pathway.
  • GOLPH3 promotes cell transformation and tumor growth.
  • GOLPH3 is implicated in protein trafficking, receptor recycling, and glycosylation.

Conclusions:

  • GOLPH3 functions as an oncoprotein by enhancing mTOR signaling, thereby promoting tumor growth.
  • Deregulation of GOLPH3-mediated cellular processes like protein trafficking and glycosylation may contribute to cancer pathogenesis.
  • Further understanding of GOLPH3's mechanisms could lead to novel therapeutic strategies for cancer treatment.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Second Messengers01:15

Amplifying Signals via Second Messengers

Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and produces two-second...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...